Skip to main content

Table 2 Screening of gatifloxacin and its synthesized derivatives using whole blood for their immune modulating inhibitory properties

From: Identification of anti-inflammatory and other biological activities of 3-carboxamide, 3-carbohydrazide and ester derivatives of gatifloxacin

Compound CPM Reading Inhibition% IC50 ± SD
Conc (μg/mL) 50 12.5 3.12 50 12.5 3.12  
4 18538.3 25229.4 29076.6 45.86 26.32 15.09 >50
5 476.3 33339.6 33370.4 97.6 −70.7 −70.9 24 ± 0.5
6 10678.5 22012.4 30970.5 45.3 −12.7 −58.6 23.9 ± 9
7 286.6 4554.4 18804.47 99.16 86.7 45.09 3.7 ± 0.1
8 6988.7 46099.7 40114.8 64.2 −136 −105.4 35.5 ± 0.4
9 16087.9 40831.9 40689 17.6 −109.1 −108.3 43.5
10 40893.6 46979.2 45283.2 −109.4 −140.5 −131.8 >50
11 13122.8 33977.4 35965.9 32.8 −74 −84.1 37.5 ±1.5
12 13691.3 41857.5 39169.8 30 −114.3 −100.5 40.7 ± 0.5
13 42380 70222.1 52258.6 −23.7 −105.05 −52.59 >50
14 257.3 2182.5 10766.9 98.7 88.8 44.9 <3.12
15 7470.6 29308.1 32117.4 61.8 −50.1 −64.4 27 ± 2.6
16 34845.8 43188.6 38111.9 −78.4 −121.1 −95.1 >50
17 10892.5 31624.6 35370.22 44.2 −61.9 −81.1 33.0 ± 0.8
18 27012.8 30291.9 30529.1 −38.3 −55.1 −56.3 >50
19 117 14599.9 22362.3 99.4 25.2 −14.5 6.8 ± 0.3
20 2932.7 14825.1 22921.5 85 24 −17.4 8.8 ± 2.8
Gatifloxacin 24450.9 38657.7 33427.3 −25.2 −97.9 −71.1 > 50
Standard 654.2 1906.8 1945.7 98.089 94.432 94.318 < 3.12